{"filing":{"accession_number":"0001549595-26-000034","cik":"0001549595","ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"nrix-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/nrix-20260611.htm"},"events":[{"id":5480,"run_id":4803,"accession_number":"0001549595-26-000034","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Nurix disclosed updated Phase 1a/1b clinical trial data for its lead BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026, including expanded safety findings across 142 patients and an 83% objective response rate in relapsed/refractory patients, along with new Phase 1b cohort data in earlier-line treatment settings.","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6080,"accession_number":"0001549595-26-000034","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Nurix disclosed updated clinical data from a Phase 1a/1b study of its BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026. While clinical trial progress can be material to biotech investors, this disclosure does not fit neatly into the standard taxonomy categories (not an earnings release, not an executive change, not M\u0026A, not a restatement or impairment). The Item 7.01 Regulation FD framing and the explicit disclaimer that the information is not deemed an admission of materiality suggest the company is treating this as a routine clinical update rather than a material event trigger, though the data itself may be significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:08:10.461325+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6081,"accession_number":"0001549595-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports updated Phase 1 clinical trial data for bexobrutideg (NX-5948), a lead pipeline asset, including expanded safety findings across 142 patients, efficacy results with an 83% ORR in Phase 1a relapsed/refractory CLL/SLL patients, and new Phase 1b cohort data in earlier-line treatment settings. While this is material clinical progress for a biopharmaceutical company's development program, it does not fit the more specific event categories (not an earnings release, M\u0026A activity, impairment, litigation, or cybersecurity incident). Clinical trial updates are typically disclosed under Item 8.01 and are material to investors assessing pipeline value and regulatory pathway prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:08:10.461325+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6080,"accession_number":"0001549595-26-000034","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Nurix disclosed updated clinical data from a Phase 1a/1b study of its BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026. While clinical trial progress can be material to biotech investors, this disclosure does not fit neatly into the standard taxonomy categories (not an earnings release, not an executive change, not M\u0026A, not a restatement or impairment). The Item 7.01 Regulation FD framing and the explicit disclaimer that the information is not deemed an admission of materiality suggest the company is treating this as a routine clinical update rather than a material event trigger, though the data itself may be significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:08:10.461325+00:00","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-11"},{"id":6081,"accession_number":"0001549595-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports updated Phase 1 clinical trial data for bexobrutideg (NX-5948), a lead pipeline asset, including expanded safety findings across 142 patients, efficacy results with an 83% ORR in Phase 1a relapsed/refractory CLL/SLL patients, and new Phase 1b cohort data in earlier-line treatment settings. While this is material clinical progress for a biopharmaceutical company's development program, it does not fit the more specific event categories (not an earnings release, M\u0026A activity, impairment, litigation, or cybersecurity incident). Clinical trial updates are typically disclosed under Item 8.01 and are material to investors assessing pipeline value and regulatory pathway prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:08:10.461325+00:00","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-11"}]}